Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin
- 27 February 2008
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 84 (3), 326-331
- https://doi.org/10.1038/clpt.2008.10
Abstract
Initiation of warfarin therapy using trial‐and‐error dosing is problematic. Our goal was to develop and validate a pharmacogenetic algorithm. In the derivation cohort of 1,015 participants, the independent predictors of therapeutic dose were: VKORC1 polymorphism −1639/3673 G>A (−28% per allele), body surface area (BSA) (+11% per 0.25 m2), CYP2C9*3 (−33% per allele), CYP2C9*2 (−19% per allele), age (−7% per decade), target international normalized ratio (INR) (+11% per 0.5 unit increase), amiodarone use (−22%), smoker status (+10%), race (−9%), and current thrombosis (+7%). This pharmacogenetic equation explained 53–54% of the variability in the warfarin dose in the derivation and validation (N= 292) cohorts. For comparison, a clinical equation explained only 17–22% of the dose variability (P < 0.001). In the validation cohort, we prospectively used the pharmacogenetic‐dosing algorithm in patients initiating warfarin therapy, two of whom had a major hemorrhage. To facilitate use of these pharmacogenetic and clinical algorithms, we developed a nonprofit website, http://www.WarfarinDosing.org. Clinical Pharmacology & Therapeutics (2008); 84, 3, 326–331 doi:10.1038/clpt.2008.10Keywords
This publication has 41 references indexed in Scilit:
- Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral AnticoagulationCirculation, 2007
- Genetic-based dosing in orthopedic patients beginning warfarin therapyBlood, 2007
- Population variation in VKORC1 haplotype structureJournal of Thrombosis and Haemostasis, 2006
- The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirementThrombosis and Haemostasis, 2006
- Functional Characterization of Novel Allelic Variants of CYP2C9 Recently Discovered in Southeast AsiansThe Journal of pharmacology and experimental therapeutics, 2005
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseThe New England Journal of Medicine, 2005
- Prospective dosing of warfarin based on cytochrome P-450 2C9 genotypeThrombosis and Haemostasis, 2005
- Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarinThrombosis and Haemostasis, 2004
- Initiating and Maintaining Patients on Warfarin Anticoagulation: The Importance of MonitoringJournal of Cardiovascular Pharmacology and Therapeutics, 1999
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999